3/16/2012

The NIH's National Institute of Neurological Disorders and Stroke awarded Marker Gene Technologies a Phase II small business innovation research grant to help advance its screening technology for lysosomal storage disease drugs. Marker will use the three-year grant worth $1.6 million to develop live cell and tissue tests for drug candidates.

Related Summaries